GlassScriptPhysician profile
Demond C White
NPI 1750524856
$12,302.92
in general payments reported to CMS, 2019-2025
57 companies · $1,394 in 2025
The $1,394 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,248 · 2020: $1,172 · 2021: $1,595 · 2022: $2,162 · 2023: $1,960 · 2024: $1,772 · 2025: $1,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,126.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,345.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,139.86 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $932.66 | 2019-2025 | |
| Amgen INC. | $842.84 | 2019-2025 | Evenity, Prolia, Otezla |
| Abbvie INC. | $732.75 | 2020-2025 | Ubrelvy, Qulipta |
| Lilly USA, LLC | $722.93 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $656.70 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $460.99 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $387.68 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $332.88 | 2019-2023 | |
| Allergan, INC. | $319.55 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $278.82 | 2019-2022 | |
| Glaxosmithkline, LLC. | $274.47 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Daiichi Sankyo INC. | $272.65 | 2019-2023 | Injectafer |
| Abbott Laboratories | $253.95 | 2019-2025 | Freestyle Libre 3 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Demond White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.